Selvita S.A. – Product Pipeline Review

Global Markets Direct’s, ‘Selvita S.A. – Product Pipeline Review – 2016’, provides an overview of the Selvita S.A.’s pharmaceutical research and development focus.

The report provides comprehensive information on the therapeutics under development by Selvita S.A., complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the pipeline therapeutic landscape of Selvita S.A.

The report provides overview of Selvita S.A. including its business description, key facts, and locations and subsidiaries

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report assesses Selvita S.A.’s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report features Selvita S.A.’s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

Reasons to buy

Evaluate Selvita S.A.’s strategic position with total access to detailed information on its product pipeline

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Selvita S.A.

Identify potential new clients or partners in the target demographic

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Selvita S.A.’s pipeline depth and focus of pipeline therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 4

Selvita S.A. Snapshot 5

Selvita S.A. Overview 5

Key Information 5

Key Facts 5

Selvita S.A. - Research and Development Overview 6

Key Therapeutic Areas 6

Selvita S.A. - Pipeline Review 10

Pipeline Products by Stage of Development 10

Pipeline Products - Monotherapy 11

Selvita S.A. - Pipeline Products Glance 12

Selvita S.A. - Early Stage Pipeline Products 12

Preclinical Products/Combination Treatment Modalities 12

Discovery Products/Combination Treatment Modalities 13

Selvita S.A. - Drug Profiles 14

SEL-120 14

Product Description 14

Mechanism of Action 14

R&D Progress 14

SEL-12034 16

Product Description 16

Mechanism of Action 16

R&D Progress 16

SEL-201 18

Product Description 18

Mechanism of Action 18

R&D Progress 18

SEL-24 19

Product Description 19

Mechanism of Action 19

R&D Progress 19

SEL-24A1 21

Product Description 21

Mechanism of Action 21

R&D Progress 21

SEL-24B489 22

Product Description 22

Mechanism of Action 22

R&D Progress 22

SEL-300 24

Product Description 24

Mechanism of Action 24

R&D Progress 24

SLV-2436 25

Product Description 25

Mechanism of Action 25

R&D Progress 25

Small Molecules to Inhibit Kinase for Oncology 26

Product Description 26

Mechanism of Action 26

R&D Progress 26

SEL-128 27

Product Description 27

Mechanism of Action 27

R&D Progress 27

SEL-212 28

Product Description 28

Mechanism of Action 28

R&D Progress 28

SEL-303 29

Product Description 29

Mechanism of Action 29

R&D Progress 29

Small Molecules for Oncology 30

Product Description 30

Mechanism of Action 30

R&D Progress 30

Small Molecules for Solid Tumors and Hematological Malignancies 31

Product Description 31

Mechanism of Action 31

R&D Progress 31

Selvita S.A. - Pipeline Analysis 32

Selvita S.A. - Pipeline Products by Target 32

Selvita S.A. - Pipeline Products by Route of Administration 33

Selvita S.A. - Pipeline Products by Molecule Type 34

Selvita S.A. - Pipeline Products by Mechanism of Action 35

Selvita S.A. - Recent Pipeline Updates 36

Selvita S.A. - Dormant Projects 37

Selvita S.A. - Discontinued Pipeline Products 38

Discontinued Pipeline Product Profiles 38

SEL-113 38

Selvita S.A. - Locations and Subsidiaries 39

Head Office 39

Other Locations & Subsidiaries 39

Appendix 40

Methodology 40

Coverage 40

Secondary Research 40

Primary Research 40

Expert Panel Validation 40

Contact Us 40

Disclaimer 41

List of Tables

List of Tables

Selvita S.A., Key Information 5

Selvita S.A., Key Facts 5

Selvita S.A. – Pipeline by Indication, 2016 8

Selvita S.A. – Pipeline by Stage of Development, 2016 10

Selvita S.A. – Monotherapy Products in Pipeline, 2016 11

Selvita S.A. – Preclinical, 2016 12

Selvita S.A. – Discovery, 2016 13

Selvita S.A. – Pipeline by Target, 2016 32

Selvita S.A. – Pipeline by Route of Administration, 2016 33

Selvita S.A. – Pipeline by Molecule Type, 2016 34

Selvita S.A. – Pipeline Products by Mechanism of Action, 2016 35

Selvita S.A. – Recent Pipeline Updates, 2016 36

Selvita S.A. – Dormant Developmental Projects,2016 37

Selvita S.A. – Discontinued Pipeline Products, 2016 38

Selvita S.A., Subsidiaries 39

List of Figures

List of Figures

Selvita S.A. – Pipeline by Top 10 Indication, 2016 7

Selvita S.A. – Pipeline by Stage of Development, 2016 10

Selvita S.A. – Monotherapy Products in Pipeline, 2016 11

Selvita S.A. – Pipeline by Target, 2016 32

Selvita S.A. – Pipeline by Molecule Type, 2016 34

Selvita S.A. – Pipeline Products by Mechanism of Action, 2016 35

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports